Cara Therapeutics Inc. (NASDAQ:CARA) And Vifor Pharma Receive Priority Review For KOSUVA’s NDA

Cara Therapeutics Inc. (NASDAQ:CARA) and Vifor Pharma have announced that the US FDA has accepted and given Priority Review for KORSUVA’s New Drug Application (NDA). KORSUVA (difelikefalin) is a solution for moderate-to-severe pruritus treatment in hemodialysis patients.

Phase II studies’ data supported NDA filing

The PDUFA target date has been set for 23 August 2021, and the regulatory agency confirmed that it is not planning any advisory committee meeting to